Cargando…

Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis

Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lubowicka, Emilia, Zbucka-Kretowska, Monika, Sidorkiewicz, Iwona, Zajkowska, Monika, Gacuta, Ewa, Puchnarewicz, Andrzej, Chrostek, Lech, Szmitkowski, Maciej, Ławicki, Sławomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242253/
https://www.ncbi.nlm.nih.gov/pubmed/30820752
http://dx.doi.org/10.1007/s12253-019-00626-z
_version_ 1783537205527969792
author Lubowicka, Emilia
Zbucka-Kretowska, Monika
Sidorkiewicz, Iwona
Zajkowska, Monika
Gacuta, Ewa
Puchnarewicz, Andrzej
Chrostek, Lech
Szmitkowski, Maciej
Ławicki, Sławomir
author_facet Lubowicka, Emilia
Zbucka-Kretowska, Monika
Sidorkiewicz, Iwona
Zajkowska, Monika
Gacuta, Ewa
Puchnarewicz, Andrzej
Chrostek, Lech
Szmitkowski, Maciej
Ławicki, Sławomir
author_sort Lubowicka, Emilia
collection PubMed
description Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag – by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC – 93.10%, II – 82.76%, III and IV – 96.88%, total group – 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis.
format Online
Article
Text
id pubmed-7242253
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-72422532020-06-03 Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis Lubowicka, Emilia Zbucka-Kretowska, Monika Sidorkiewicz, Iwona Zajkowska, Monika Gacuta, Ewa Puchnarewicz, Andrzej Chrostek, Lech Szmitkowski, Maciej Ławicki, Sławomir Pathol Oncol Res Original Article Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag – by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC – 93.10%, II – 82.76%, III and IV – 96.88%, total group – 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis. Springer Netherlands 2019-02-28 2020 /pmc/articles/PMC7242253/ /pubmed/30820752 http://dx.doi.org/10.1007/s12253-019-00626-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lubowicka, Emilia
Zbucka-Kretowska, Monika
Sidorkiewicz, Iwona
Zajkowska, Monika
Gacuta, Ewa
Puchnarewicz, Andrzej
Chrostek, Lech
Szmitkowski, Maciej
Ławicki, Sławomir
Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
title Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
title_full Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
title_fullStr Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
title_full_unstemmed Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
title_short Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
title_sort diagnostic power of cytokine m-csf, metalloproteinase 2 (mmp-2) and tissue inhibitor-2 (timp-2) in cervical cancer patients based on roc analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242253/
https://www.ncbi.nlm.nih.gov/pubmed/30820752
http://dx.doi.org/10.1007/s12253-019-00626-z
work_keys_str_mv AT lubowickaemilia diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT zbuckakretowskamonika diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT sidorkiewicziwona diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT zajkowskamonika diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT gacutaewa diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT puchnarewiczandrzej diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT chrosteklech diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT szmitkowskimaciej diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis
AT ławickisławomir diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis